-
Dr. Reck Shared Advancements in Thoracic Oncology and Immunotherapy
The 2023 European Lung Cancer Congress (ELCC) proved to be a momentous event, bringing together global experts in thoracic oncology. Organized jointly by the International Association for the Study of…
-
Incorporating Cytarabine in Pre-treatment for Haploidentical Stem Cell Transplantation in Extramedullary Acute Leukemia: Safety and Efficacy
Allogeneic hematopoietic stem cell transplantation is among the most effective methods for treating malignant hematopoietic tumors. However, for extramedullary leukemia, even with high-intensity chemotherapy and transplantation, the recurrence rate remains high. To improve the prognosis, it’s essential to optimize the pre-treatment plan and reduce recurrence.At this EBMT annual meeting,Dr. Min Xiong from Hebei Yanda Ludaopei…
-
Dr. Hui Wang: Unlocking a New Approach to MRD Testing in Acute Myeloid Leukemia
The 49th European Bone Marrow Transplantation Annual Meeting (EBMT 2023) took place in Paris, France, from April 23 to 26, 2023. Experts and scholars from various countries gathered to present exciting advancements in research. In the field of blood tests, the fifty-year anniversary of flow cytometry coincided with this year’s conference. Over the past half-century,…
-
Dr. Xingyu Cao: Post-transplant maintenance therapy with Chidamide in T-ALL patients is expected to reduce relapse and improve survival
Acute T-cell lymphoblastic leukemia (T-ALL) is a highly heterogeneous malignant tumor of the hematopoietic system caused by the malignant transformation of T-cell precursors. It has significant differences from B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in clinical features, cellular genetics, molecular biology, and abnormal signal transduction pathways. T-ALL accounts for 10%-15% in children and 20%-25% in…
-
How to choose the maintenance treatment plan after HSCT for R/R malignant hematological patients?
Relapse/refractory (R/R) has always been a difficult point in the clinical treatment of malignant hematological tumors. Hematopoietic stem cell transplantation (HSCT) is an important treatment for these patients to achieve long-term survival. Subsequent maintenance treatment is essential to consolidate the effects of HSCT and prevent disease recurrence. Therefore, researchers have been focusing on optimizing the…
-
ESMO 2023丨Professor Feng Jin: CLEVER Study – Repurposing Old Drugs for Targeting Dormant Tumor Cells to Prevent High-Risk Breast Cancer Recurrence
Editor’s note: Previous studies have indicated a close association between disseminated tumor cells (DTC) in the bone marrow and breast cancer recurrence. At the 2023 ESMO conference, data from the…
-
ESMO 2023 China Voice | Professor Fei Han: Hot Research on Nasopharyngeal Carcinoma in China, Innovative Drug Efficacy Worth Expecting!
Editor’s Note: The ESMO Annual Meeting in 2023 was held grandly in Madrid, Spain, from October 20th to 24th. As an authoritative annual event in the field of oncology, the…
-
ESMO Exclusive Interview | Dr.Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression
Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer Background The clinical outcomes of metastatic colorectal cancer (mCRC) therapies are limited. Guanylyl cyclase 2C (GCC)…
Connecting Medical Expertise through Media